Cannabinoid compositions and dosage forms for intranasal or inhalational delivery

1 . A method of treating a neurological condition in a patient identified as in need thereof comprising the step of:

administering to the patient, intranasally or through inhalation, formulated to target the brain of the patient a pharmaceutical composition comprising

(i) a therapeutically effective amount of a cannabinoid selected from Δ 9 -THC and cannabinodiol (CBD), or a pharmaceutically acceptable salt or solvate thereof; and

(ii) an amphiphilic copolymer comprising at least one hydrophilic component comprising polyethylene glycol (PEG) and at least one hydrophobic component selected from polycaprolactone (PCL), polylactic acid (PLA), poly lactide co-glycolide (PLGA), and a combination thereof;

wherein the ratio of the cannabinoid to the amphiphilic copolymer is greater than 1:10 by weight, and said cannabinoid is encapsulated in said amphiphilic copolymer, and wherein said neurological condition is selected from Alzheimer's disease, Parkinson's disease, neuropathic pain, spasticity, spinal-cord-injury-induced pain, migraines, multiple sclerosis, Tourette Syndrome, and post-traumatic stress disease (PTSD).

2 . The method of claim 1 , wherein said hydrophilic and hydrophobic components are in a ratio, by number average molecular weight, of about 1:1 to 1:5.

3 . The method of claim 1 , wherein said hydrophilic component is polyethylene glycol (PEG) having a number average molecular weight of about 2000 and said hydrophobic component is poly lactide co-glycolide (PLGA) having a molecular weight of about 4500.

4 . The method of claim 1 , wherein said therapeutically effective amount of cannabinoid is about 0.2 to 7.5 mg.

5 . The method of claim 1 , wherein said pharmaceutical composition is administered once daily or twice daily.